Medication Alert for Singulair (Montelukast) , EpiPen, Zantac (Ranitidine)

1) Singulair
Singulair (generic version is known as montelukast) is used to treat asthma and allergic rhinitis.
The U.S. Food and Drug Administration (FDA) is requiring a boxed warning for montelukast strengthening an existing warning about the neuropsychiatric adverse effects. This includes symptoms such as agitation, depression, sleeping problems, and suicidal thoughts and actions. The new warning advises use of singulair for allergic rhinitis only when conventional treatments have failed. Visit FDA website and AAAAI's website for more information. Please contact your healthcare provider for additional questions.

2) EpiPen
The Food and Drug Administration (FDA) has announced auto-injector errors related to device malfunctions and user administration. The device malfunction is due to potentially delayed injection or prevention from properly injecting due to:

1. Device failure from spontaneous activation caused by using sideways force to remove the blue safety release
2. Device failure from inadvertent or spontaneous activation due to a raised blue safety release
3. Difficulty removing the device from the carrier tube
4. User errors

Please evaluate your EpiPen device for the malfunction. If you notice any of the above noted issues contact Mylan Customer Relations at 1-800-796-9526 to obtain a replacement device(s) at no additional cost. Visit the FDA website for additional information and patient instructions.

3) Zantac (Ranitidine)
Improper storage of Zantac (Ranitidine) can cause contamination with NDMA (*N*-nitrosodimethylamine). NDMA is a known human carcinogen. This has led the Food and Drug Administration to call for manufacturers of the drug to remove all product, both over-the-counter and prescription forms, from the market. Visit FDA website for more information.

--

Pooja Oza Patel, MD
Dr, Diane L.Ozog & Associates
1331 W. 75th Street, Suite 303
Naperville, IL 60540